US 12,467,037 B2
Platform for generating safe cell therapeutics
Richard Klemke, La Jolla, CA (US); and Huawei Wang, San Diego, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, La Jolla, CA (US)
Filed on Nov. 22, 2022, as Appl. No. 17/992,372.
Application 17/992,372 is a continuation of application No. 17/665,130, filed on Feb. 4, 2022, granted, now 11,674,121.
Application 17/665,130 is a continuation of application No. 17/159,595, filed on Jan. 27, 2021, granted, now 11,248,213, issued on Feb. 15, 2022.
Application 17/159,595 is a continuation of application No. 16/902,420, filed on Jun. 16, 2020, granted, now 10,960,071, issued on Mar. 30, 2021.
Application 16/902,420 is a continuation of application No. 16/636,249, abandoned, previously published as PCT/US2018/045686, filed on Aug. 7, 2018.
Claims priority of provisional application 62/542,133, filed on Aug. 7, 2017.
Prior Publication US 2023/0159897 A1, May 25, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0775 (2010.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01); A61K 35/17 (2025.01); A61K 35/28 (2015.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/215 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); C12N 15/85 (2006.01); C12N 15/88 (2006.01)
CPC C12N 5/0662 (2013.01) [A61K 9/0019 (2013.01); A61K 35/12 (2013.01); A61K 35/17 (2013.01); A61K 35/28 (2013.01); A61K 38/2066 (2013.01); A61K 38/208 (2013.01); A61K 39/001102 (2018.08); A61K 39/215 (2013.01); A61P 35/00 (2018.01); C12N 5/0646 (2013.01); C12N 5/0667 (2013.01); C12N 5/10 (2013.01); C12N 15/85 (2013.01); C12N 15/88 (2013.01); A61K 39/00 (2013.01); A61K 2039/515 (2013.01); A61K 2039/545 (2013.01); C12N 2501/999 (2013.01); C12N 2510/00 (2013.01); C12N 2513/00 (2013.01)] 30 Claims
 
1. An enucleated cell, comprising:
a) an exogenous nucleic acid encoding a gene-editing factor; and
b) one or more intracellular organelles sufficient for in vivo synthesis of the gene-editing factor in the absence of a nucleus.